CD8A and disease arising from reactivation of latent virus: Ruxolitinib can modulate dendritic cell function, leading to impaired CD4+ and CD8+ T-cell priming.[7] Additionally, inhibition of JAK1 impairs cytokine production, resulting in an increased risk of reactivation of latent infections and potentially life-threatening opportunistic infections.